High-resolution serum proteomic profiling of Alzheimer disease samples reveals disease-specific, carrier-protein-bound mass signatures

被引:109
作者
Lopez, MF
Mikulskis, A
Kuzdzal, S
Bennett, DA
Kelly, J
Golenko, E
DiCesare, J
Denoyer, E
Patton, WF
Ediger, R
Sapp, L
Ziegert, T
Lynch, C
Kramer, S
Whiteley, GR
Wall, MR
Mannion, DP
Della Cioppa, G
Rakitan, JS
Wolfe, GM
机构
[1] PerkinElmer Life & Analyt Sci, Boston, MA 02118 USA
[2] PerkinElmer Life & Analyt Sci, Shelton, CT USA
[3] Rush Univ, Med Ctr, Rush Alzheimers Dis Ctr, Chicago, IL 60612 USA
[4] PerkinElmer Life & Analyt Sci, Beaconsfield, Bucks, England
[5] SAIC Frederick Inc, NCI, Clin Prote Reference Lab, Gaithersburg, MD USA
[6] Predict Diagnost Inc, Vacaville, CA USA
关键词
D O I
10.1373/clinchem.2005.053090
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background. Researchers typically search for disease markers using a "targeted" approach in which a hypothesis about the disease mechanism is tested and experimental results either confirm or disprove the involvement of a particular gene or protein in the disease. Recently, there has been interest in developing disease diagnostics based on unbiased quantification of differences in global patterns of protein and peptide masses, typically in blood from individuals with and without disease. We combined a suite of methods and technologies, including novel sample preparation based on carrier-protein capture and biomarker enrichment, high-resolution mass spectrometry, a unique cohort of well-characterized persons with and without Alzheimer disease (AD), and powerful bioinformatic analysis, that add statistical and procedural robustness to biomarker discovery from blood. Methods: Carrier-protein-bound peptides were isolated from serum samples by affinity chromatography, and peptide mass spectra were acquired by a matrixassisted laser desorptionlionization (MALDI) orthogo-nal time-of-flight (O-TOF) mass spectrometer capable of collecting data over a broad mass range (100 to > 300 000 Da) in a single acquisition. Discriminatory analysis of mass spectra was used to process and analyze the raw mass spectral data. Results: Coupled with the biomarker enrichment protocol, the high-resolution MALDI O-TOF mass spectra provided informative, reproducible peptide signatures. The raw mass spectra were analyzed and used to build discriminant disease models that were challenged with blinded samples for classification. Conclusions: Carrier-protein enrichment of disease biomarkers coupled with high-resolution mass spectrometry and discriminant pattern analysis is a powerful technology for diagnostics and population screening. The mass fingerprint model successfully classified blinded AD patient and control samples with high sensitivity and specificity. (c) 2005 American Association for Clinical Chemistry.
引用
收藏
页码:1946 / 1954
页数:9
相关论文
共 27 条
[1]   Signal in noise: Evaluating reported reproducibility of serum proteomic tests for ovarian cancer [J].
Baggerly, KA ;
Morris, JS ;
Edmonson, SR ;
Coombes, KR .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (04) :307-309
[2]   Surfaced-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) differentiation of serum protein profiles of BRCA-1 and sporadic breast cancer [J].
Becker, S ;
Cazares, LH ;
Watson, P ;
Lynch, H ;
Semmes, OJ ;
Drake, RR ;
Laronga, C .
ANNALS OF SURGICAL ONCOLOGY, 2004, 11 (10) :907-914
[3]   Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions [J].
Bennett, DA ;
Schneider, JA ;
Bienias, JL ;
Evans, DA ;
Wilson, RS .
NEUROLOGY, 2005, 64 (05) :834-841
[4]   Natural history of mild cognitive impairment in older persons [J].
Bennett, DA ;
Wilson, RS ;
Schneider, JA ;
Evans, DA ;
Beckett, LA ;
Aggarwal, NT ;
Barnes, LL ;
Fox, JH ;
Bach, J .
NEUROLOGY, 2002, 59 (02) :198-205
[5]   Three-dimensional power Doppler ultrasound improves the diagnostic accuracy for ovarian cancer prediction [J].
Cohen, LS ;
Escobar, PF ;
Scharm, C ;
Glimco, B ;
Fishman, DA .
GYNECOLOGIC ONCOLOGY, 2001, 82 (01) :40-48
[6]   High-resolution serum proteomic features for ovarian cancer detection [J].
Conrads, TP ;
Fusaro, VA ;
Ross, S ;
Johann, D ;
Rajapakse, V ;
Hitt, BA ;
Steinberg, SM ;
Kohn, EC ;
Fishman, DA ;
Whiteley, G ;
Barrett, JC ;
Liotta, LA ;
Petricoin, EF ;
Veenstra, TD .
ENDOCRINE-RELATED CANCER, 2004, 11 (02) :163-178
[7]   Clinical proteomics: Are we there yet? [J].
Cottingham, K .
ANALYTICAL CHEMISTRY, 2003, 75 (21) :472A-476A
[8]   Point - Proteomic patterns in biological fluids: Do they represent the future of cancer diagnostics? [J].
Diamandis, EP .
CLINICAL CHEMISTRY, 2003, 49 (08) :1272-1275
[9]   Biological markers for therapeutic trials in Alzheimer's disease - Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease [J].
Frank, RA ;
Galasko, D ;
Hampel, H ;
Hardy, J ;
de Leon, MJ ;
Mehta, PD ;
Rogers, J ;
Siemers, E ;
Trojanowski, JQ .
NEUROBIOLOGY OF AGING, 2003, 24 (04) :521-536
[10]   Alzheimer disease in the US population - Prevalence estimates using the 2000 census [J].
Hebert, LE ;
Scherr, PA ;
Bienias, JL ;
Bennett, DA ;
Evans, DA .
ARCHIVES OF NEUROLOGY, 2003, 60 (08) :1119-1122